Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MDX2001 |
| Synonyms | |
| Therapy Description |
MDX2001 is a tetraspecific antibody that targets MET and TROP2 on tumor cells and CD3 and CD28 expressed on T-cells, which potentially induces T-cell activation and antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MDX2001 | MDX-2001|MDX 2001 | CD3 Antibody 119 MET Antibody 38 TROP2 Antibody 18 | MDX2001 is a tetraspecific antibody that targets MET and TROP2 on tumor cells and CD3 and CD28 expressed on T-cells, which potentially induces T-cell activation and antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06239194 | Phase Ib/II | MDX2001 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |